Table 1.
Demographic and clinical characteristics of 99 psoriatic patients receiving interleukin-17A blockade (secukinumab/Cosentyx®).
| All N = 99 |
PASI-90+ n = 39 |
PASI-90– n = 60 |
p | |
|---|---|---|---|---|
| Age†, mean (±SD), years | 44.73 (±13.15) | 43.56 (±13.46) | 45.48 (±13.00) | 0.481 |
| Disease duration, years | 17.19 (±8.83) | 14.82 (±8.65) | 18.73 (±8.67) | 0.031* |
| Sex | ||||
| Male | 75 (75.8) | 24 (61.5) | 51 (85.0) | 0.015* |
| Female | 24 (24.2) | 15 (38.5) | 9 (15.0) | |
| BW, kg | 80.33 (18.07) | 74.40 (14.23) | 84.18 (19.33) | 0.008* |
| BMI, mean (±SD), kg/m2 | 28.92 (±5.783) | 27.24 (±4.73) | 30.00 (±6.25) | 0.021* |
| <24 | 18 (18.2%) | 12 (30.8%) | 6 (10.0%) | |
| 24–27 | 23 (23.2%) | 8 (20.5%) | 15 (25.0%) | |
| 27–30 | 19 (19.2%) | 7 (17.9%) | 12 (20.0%) | |
| >30 | 39 (39.4%) | 12 (30.8%) | 27 (45.0%) | |
| Systemic agents-naive | 68 (68.7%) | 22 (56.4%) | 46 (76.7%) | 0.046* |
| Biologics-naïve | 45 (45.5%) | 25 (64.1%) | 20 (33.3%) | 0.004* |
| Baseline, week 0, PASI (±SD) | 19.21 (±11.09) | 19.04 (±10.16) | 19.31 (±11.74) | 0.906 |
| PASI (±SD), week 12 | 3.23 (±3.92) | 1.05 (±2.08) | 4.64 (±4.19) | <0.0001* |
| Treated, week 24, PASI (±SD) | 3.79 (±4.83) | 0.35 (±0.67) | 6.03 (±5.05) | <0.0001* |
| Current smoking | ||||
| No | 49 (49.5) | 24 (61.5) | 25 (41.7) | 0.066 |
| Yes | 50 (50.5) | 15 (438.5) | 35 (58.3) | |
| Current drinking | ||||
| No | 57 (57.6) | 26 (66.7) | 31 (51.7) | 0.152 |
| Yes | 42 (42.4) | 13 (33.3) | 29 (48.3) | |
| Hypertension | ||||
| No | 59 (59.6) | 26 (66.7) | 33 (55.0) | 0.297 |
| Yes | 40 (40.4) | 13 (33.3) | 27 (45.0) | |
| Diabetes | ||||
| No | 73 (73.7) | 33 (84.6) | 40 (66.7) | 0.062 |
| Yes | 26 (26.3) | 6 (15.4) | 20 (33.3) | |
| Dyslipidemia | 0.526 | |||
| No | 61 (61.6) | 26 (66.7) | 35 (58.3) | |
| Yes | 38 (38.4) | 13 (33.3) | 25 (41.7) | |
| Hyperuricemia | ||||
| No | 59 (59.6) | 26 (66.7) | 33 (55.0) | 0.297 |
| Yes | 40 (40.4) | 13 (33.3) | 27 (45.0) | |
| Psoriatic arthritis | ||||
| No | 53 (53.5) | 22 (56.4) | 31 (51.7) | 0.684 |
| Yes | 46 (46.5) | 17 (43.6) | 29 (48.3) | |
†
Age at treatment.
*
p < 0.05 was considered statistically significant.
AIP, Atherogenic Index of Plasma (AIP = log(triglyceride/high-density lipoprotein cholesterol); BMI, body mass index; BW, body weight; PASI, Psoriasis Area and Severity Index; SD, standard deviation.